NEUROONE MEDICAL TECHNOLOGIES Corp
NMTC Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$0.85
KIRA · Stoqly’s AI analyst, in plain words
- NEUROONE MEDICAL TECHNOLOGIES Corp had $9.1M of revenue in fiscal 2025, up 163.5% on the year before.
- Its operating margin was −46.5%, up 297.8 pts: of every 100 in sales, about −46 is left after running the business.
- NEUROONE MEDICAL TECHNOLOGIES Corp lost $3.6M in fiscal 2025.
- Free cash flow was −$2.9M in fiscal 2025, −32.1% of revenue.
Market cap
$7.4M
P/E
—
Revenue
$9.1M
Net income
−$3.6M
Free cash flow
−$2.9M
Operating margin
−46.5%
NEUROONE MEDICAL TECHNOLOGIES Corp in 30 seconds · fiscal 2025
Are sales growing?
+163.5%
Yes. Sales grew 163.5% last year.
Does it make a profit?
−39.6%
No. It lost money last year.
Does profit turn into cash?
−32.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What NEUROONE MEDICAL TECHNOLOGIES Corp does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Dec 17, 2025
- Legal name
- NEUROONE MEDICAL TECHNOLOGIES Corp
- CIK
- 0001500198
NEUROONE MEDICAL TECHNOLOGIES Corp · NMTC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.2M | $2.0M | $3.5M | $9.1M |
| Revenue growth | — | −3.9% | 1,040.4% | 76.9% | 163.5% |
| Net interest income | −$0.0M | — | — | — | — |
| Gross margin | −54.9% | −41.4% | 23.4% | 31.3% | 56.5% |
| Operating margin | −5,737.3% | −5,859.1% | −612.3% | −344.3% | −46.5% |
| Net income | −$9.9M | −$10.0M | −$11.9M | −$12.3M | −$3.6M |
| Net margin | −5,585.7% | −5,840.9% | −607.4% | −356.7% | −39.6% |
| Diluted EPS | −$0.93 | −$0.63 | −$0.65 | −$0.46 | −$0.09 |
| Cash | |||||
| Cash from operations | −$8.6M | −$7.5M | −$12.9M | −$11.0M | −$2.8M |
| Capital expenditure | $0.1M | $0.3M | $0.4M | $0.1M | $0.1M |
| Free cash flow | −$8.7M | −$7.8M | −$13.3M | −$11.1M | −$2.9M |
| FCF margin | −4,868.0% | −4,553.0% | −679.7% | −322.4% | −32.1% |
| Share count change | — | 49.6% | 13.3% | 47.7% | 50.0% |
| Debt and strength | |||||
| Cash and short-term investments | $6.9M | $11.1M | $5.3M | $1.5M | $6.6M |
| Debt incl. finance leases | $0.2M | $0.1M | $0.2M | — | — |
| Shareholders' equity | $6.6M | $9.6M | $6.2M | $0.8M | $7.1M |
| Current ratio | 6.2x | 3.9x | 4.1x | 2.1x | 4.4x |
| Interest coverage | −3,296.2x | — | — | — | — |
| Returns and quality | |||||
| Return on capital | — | — | −849.9% | — | — |
| Return on equity | −230.8% | −123.8% | −149.6% | −348.4% | −91.3% |
| Return on tangible equity | −155.0% | −105.3% | −192.5% | −1,632.2% | −51.3% |
| Piotroski F-score | — | 4 | 3 | 3 | 5 |
| Altman Z'' | −15.4 | −10.4 | −27.1 | −57.3 | −19.6 |
Insiders bought, 12 months
$0.7M
1 insider
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
NEUROONE MEDICAL TECHNOLOGIES Corp · NMTC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.85 a share, the company is worth $7.4M.
Source: SEC EDGAR XBRL filings (CIK 0001500198). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.